Transforming Lives
Innovation, fueled by science and a passion for patients
PTC is an established global biopharmaceutical company that delivers transformative therapies for people living with rare diseases. For 25 years, we have been harnessing our scientific platforms to create new therapies that address the underlying cause of the disease and deliver on our promise to create more moments for those who count on us.
Focused research platforms at work for patients
Challenging what's possible
Harnessing groundbreaking science for patients has led to many firsts – the first approved treatment for Duchenne in the world, the first approved gene therapy directly infused into the brain, and the first approved small molecule splicing modifier. Our innovative pipeline continues to expand as we discover and develop treatments using the newest technologies available.
Clinical Trials
We are committed to making progress in rare disease through clinical trial research.
We love what we do
PTC employees are working to change patients’ lives every single day.
We are motivated by our patients and the drive for them to have more moments with their families, made possible in part by our research and therapies.
If you’re looking to take on rewarding work with inspiring colleagues, come grow with us.

Making headlines
-
PRESS RELEASE
PTC Therapeutics Receives Positive CHMP Opinion for Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)
PTC Therapeutics announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion on the marketing authorization application for Sephience™ (sepiapterin) for the treatment of children and adults living with phenylketonuria (PKU). The opinion includes a broad label inclusive of all ages and disease severities. -
PRESS RELEASE
PTC Therapeutics to Participate at Upcoming Investor Conferences
PTC will be presenting at four upcoming investor conferences this May and June, including: Bank of America Securities 2025 Health Care Conference, RBC Capital Markets Global Healthcare Conference 2025, William Blair 45th Annual Growth Stock Conference 2025 and Goldman Sachs 46th Annual Global Healthcare Conference 2025. -
NEWSROOM
PKU Reimagined Series: Watch Emma’s Inspiring Story
At PTC Therapeutics, we’re working to help reimagine a future where people with PKU can live more freely. We’re listening to the PKU community, sharing their stories, and learning how to better serve the PKU community.